NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

ADTC update February 2015

The additions to NHSGGC Formulary agreed at ADTC, 16 February 2015, included:

Brimonidine gel (Mirvaso®) for the treatment of the erythema associated with rosacea. Brimonidine reduces erythema through direct cutaneous vasoconstriction. It can be used in conjunction with other topical treatments that treat the inflammatory lesions.

Omalizumab for chronic spontaneous urticaria in adults and adolescents over 12 years has been accepted for specialist use: the place in therapy is after inadequate response to combination therapy with H1 antihistamines (up to four times the licensed dose), leukotriene receptor antagonists (LTRA) and H2 antihistamines (as per recognised clinical guidance): a local treatment protocol is to be developed. It is expected that this will be managed through specialist urticaria clinics.

Another two new inhalers have been added to the Total Formulary. A Formulary section review is planned to consider the range of agents and devices recently introduced and how these fit with current preferred options: the outcome of this review will be published in a future edition.

  • olodaterol (Striverdi® Respimat®), single agent LABA  
  • umeclidinum and vilanterol (Anoro®), a LAMA/LABA combination  

The full list of Formulary changes are available here.